Amgen Inc.’s Stock Price Dips to $329.89: A 3.02% Decrease Reflects Market Volatility

Amgen Inc. (AMGN)

329.89 USD -10.27 (-3.02%) Volume: 2.73M

Amgen Inc.’s stock price stands at 329.89 USD, experiencing a dip of -3.02% this trading session with a trading volume of 2.73M, yet boasts a promising YTD percentage change of +30.51%, showcasing its potential for growth and resilience in the stock market.

Latest developments on Amgen Inc.

Amgen Inc. (AMGN) has been making waves in the stock market recently, with various events contributing to its current trend. The company was recently named the Official Biotech Partner by the Los Angeles Sports & Entertainment Commission ahead of the FIFA World Cup 2026. Additionally, Tema Etfs LLC disclosed a significant $3.62 million stock holding in Amgen Inc. Further boosting the stock price, Amgen saw a 28% share price gain over the past 12 months. Despite some concerns about stagnation and IRS implications, Amgen’s stock hit a 52-week high at $345.95. Analysts at Erste Group Bank upgraded Amgen’s rating to Buy, citing optimism about their obesity drug. With positive updates on pipeline developments and a strong Q3 performance, Amgen’s future earnings narrative is looking promising.

Amgen Inc. on Smartkarma

Analyst coverage of Amgen Inc on Smartkarma has been positive, with research reports from Baptista Research highlighting the company’s strong financial performance and growth prospects. In a report titled “Amgen: Diversification Through Newer Blockbusters & A Strengthening Late-Stage Pipeline Rewriting Its Growth Story!”, Amgen reported a 12% year-over-year revenue growth in Q3 2025, reaching $9.6 billion. Key products like Repatha, EVENITY, and TEZSPIRE contributed to this growth, with 16 products achieving double-digit sales increases. The report suggests a promising outlook for Amgen’s future.

Another report by Baptista Research, titled “Amgen: New Breakthroughs in Obesity, Rare Diseases, & High-Impact Therapies; But Is It Enough?”, presents a mixed assessment of Amgen’s latest earnings call. While the company reported a 9% increase in quarterly revenues driven by a 13% rise in product volumes, there are also challenges to address. The report highlights a diversified product portfolio and effective market penetration in various therapeutic areas. Overall, analyst coverage on Smartkarma indicates a cautious optimism towards Amgen Inc‘s growth potential.

A look at Amgen Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Amgen Inc. has received a mixed outlook based on the Smartkarma Smart Scores. While the company scored high in Dividend and Momentum, with a score of 5 and 4 respectively, indicating strong performance in these areas, it scored lower in Value, Growth, and Resilience. This suggests that investors may be attracted to the company’s dividend payouts and current market momentum, but should be cautious about the company’s overall growth potential and resilience in the face of challenges.

Despite some areas of concern, Amgen Inc. remains a key player in the biotechnology industry. The company’s focus on developing medicines for serious illnesses, combined with its dedication to innovation in cellular and molecular biology, positions it as a leader in the field of human therapeutics. Investors may want to keep an eye on Amgen Inc.’s performance in the coming years to see how it navigates the challenges and opportunities in the biotechnology sector.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma